In contrast, the sensitivity of IFSH for predicting final surgical margin status was low, at 21.7%. This indicates that while ...

In addition, it provides an update on advances in the implementation of hybrid imaging technologies for the surgical management of patients with cancer in conjunction with intraoperative regional ...

Discover a recent study that introduced a novel approach combining preoperative 3D printing with intraoperative ...

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 27, 2025 / (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and ...

ClearPoint achieves FDA 510(k) clearance for its Navigation Software Version 3.0, designed to standardize cell and gene therapy delivery in the United States.